[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphoma-receiving-car-t-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphoma-receiving-car-t-therapy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100632112","fecal-microbiota-transplantation-in-patients-undergoing-chimeric-antigen-receptor-t-cell-therapy-and-allogeneic-stem-cell-transplant-a-pilot-study-100632112",false,"NCT07509450","Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study","FMT","Inclusion Criteria:\n\n1. Men and women ≥ 18 years of age\n2. Diagnosis of the following:\n\n   1. Indolent or aggressive B-cell lymphoma eligible for standard or care CAR-T therapy (Cohort A), or\n   2. Patients with AML or high risk MDS with indication to undergo reduced-intensity conditioning alloSCT, with an available matched related, unrelated, or haploidentical donor (Cohort B)\n3. ECOG 0-1\n4. Adequate marrow function defined by:\n\n   1. Hemoglobin \\>80 g\u002FL without transfusion dependence within the last 7 days\n   2. Platelet count \\>20 x 109\u002FL without transfusion dependence within the last 7 days\n   3. Neutrophil count \\>1.0 x 109\u002FL without growth factor support within the last 7 days\n5. Adequate liver function as indicated by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x the institutional upper limits of normal (ULNs) value; serum total bilirubin \\\u003C 1.5 x ULN (unless documented Gilbert's syndrome)\n6. Adequate renal function as defined as creatinine clearance ≥ 30 mL\u002Fmin directly measured with a 24-hour urine collection or calculated according to the modified formula of Cockcroft-Gault equation or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) calculation\n7. Life expectancy \\>6 months\n8. Women of childbearing potential (WOCBP) who are sexually active must use highly effective methods of contraception during treatment and up to 6 months after the last dose of protocol therapy. Men who are sexually active must use highly effective methods of contraception during treatment and up to 6 months after the last dose of protocol therapy. Men require an agreement to remain abstinent (ie, refrain from heterosexual intercourse) or use a condom, and an agreement to refrain from donating sperm. Periodic abstinence and withdrawal are not acceptable methods of contraception. Fertility preservation options should be discussed. Examples of highly effective contraceptive methods include an agreement to remain abstinent (ie, refrain from heterosexual intercourse), bilateral tubal ligation, male sterilization, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.\n9. Willing and able to participate in all required evaluations and procedures in this study.\n10. Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n1. For patients undergoing alloSCT (Cohort B): plan to undergo myeloablative conditioning\n2. Use of investigational agents within the last 4 weeks before enrollment.\n3. Active or uncontrolled infection\n4. Autoimmune disorder currently being treated with disease-modifying therapy or with \\>10mg\u002Fday prednisone\n5. Inflammatory bowel disease\n6. History of intestinal perforation\n7. Gastrointestinal surgical procedure within the past 4 weeks before enrollment\n8. Pregnant or breast-feeding patients\n9. HIV infection with detectable viral load or CD4 count \\\u003C200\n10. Serologic status reflecting active hepatitis B or C infection as follows:\n\n    1. Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with detectable hepatitis B virus (HBV) DNA. (Note, patients with undetectable HBV DNA are permitted to enroll if they are on Hepatitis B suppressive therapy)\n    2. Patients with presence of hepatitis C virus (HCV) antibody and HCV RNA detectable\n11. History of infection or known colonization with antibiotic resistant organism in the last two years before enrollment (including ESBL, MRSA, VISA, VRSA, VRE, CPE)\n12. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in the study","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a single site pilot trial will evaluate the feasibility and safety of fecal microbiota transplantation (FMT) in patients with B-cell lymphoma who are undergoing CAR-T or in patients with moderate to high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing allogeneic stem cell transplantation.",[26],"Lymphoma Receiving CAR-T Therapy","RECRUITING","2026-06-09",{"date":30,"type":31},"2026-06-11","ACTUAL",{"date":33,"type":31},"2026-06-02",{"date":35,"type":20},"2029-06-02",{"name":37,"class":38},"University Health Network, Toronto","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100614810","phase-1-study-of-allo-quadcar01-t-an-allogeneic-car-t-targeting-cd19cd20-in-patients-with-relapsed-or-refractory-b-cell-malignancies-100614810","NCT07284433","Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19\u002FCD20, in Patients With Relapsed or Refractory B-Cell Malignancies","A Single-arm, Multicenter, Open-label, Phase I\u002FII Trial of Allo-QuadCAR01-T, an Allogeneic CAR-T-cell Therapy Targeting CD19 and CD20, for the Treatment of Relapsed or Refractory B-cell Malignancies","QUADvance","Inclusion Criteria:\n\n* Adults 18 years or older.\n* Diagnosed with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or chronic lymphocytic leukemia (CLL).\n* Must have received at least 2 prior lines of therapy.\n* ECOG performance status 0-1 (able to carry out daily activities).\n* Adequate organ function (heart, liver, kidneys).\n* HLA B\u002FC match with donor cells.\n* No active uncontrolled infections.\n\nExclusion Criteria:\n\n* Active CNS involvement (including PCNSL) in dose escalation cohorts; may be allowed in later cohorts with Sponsor approval.\n* Prior CAR-T within 3 months of screening, or ≥Grade 3 ICAHT from prior CAR-T.\n* Autologous stem cell transplant within 3 months.\n* Prior allogeneic stem cell transplant or solid organ transplant.\n* Prior therapy with dual CD19\u002FCD20 CAR-T.\n* Severe hypersensitivity to trial agents or similar compounds.\n* History of GvHD or post-transplant lymphoproliferative disorder.\n* Presence of La\u002FSS-B autoantibodies or related autoimmune diseases.\n* Other malignancy that may interfere with trial, except:\n\n  * Curatively treated basal\u002Fsquamous skin cancer or cervical carcinoma in situ\n  * Low-grade, early-stage prostate cancer (Gleason ≤6, Stage 1-2) with no therapy needed\n  * Adjuvant endocrine therapy for non-metastatic breast cancer (≥2 years)\n  * Any other curatively treated malignancy in remission ≥2 years\n* Active viral infection within 1 week of screening, or serious bacterial\u002Ffungal infection.\n* Hemorrhagic cystitis.\n* Active neuro-autoimmune disease (e.g., MS, Guillain-Barré, ALS).\n* Active or residual HBV, HCV, or syphilis.\n* Active HIV. History of HIV may be eligible with Sponsor approval if:\n* Neurological disorders within 6 months (e.g., stroke, dementia, Parkinson's, cerebellar disease, CNS autoimmune disease).\n* Significant cardiac disease within 6 months (e.g., MI, stent, unstable angina).\n* Primary immunodeficiency or autoimmune disease requiring systemic treatment within 1 year (unless stable and Sponsor-approved).\n* Unresolved ≥Grade 2 non-hematologic toxicity from prior therapy (except neuropathy up to Grade 2).\n* Systemic immunosuppression within 28 days.\n* Last systemic lymphoma\u002FCLL therapy (standard or investigational) within 28 days or 5 half-lives.\n* Major surgery within 14 days.\n* Local radiation within 28 days.\n* Live vaccination within 28 days.\n* Pregnant or breastfeeding.",{"count":49,"type":20},178,[51,52],"PHASE1","PHASE2","This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready to use, which can save time and reduce costs. It targets two proteins, CD19 and CD20, to lower the chance of relapse and uses gene editing to make it safer. The trial has three parts: first to find a safe dose, then to confirm it, and finally to test how well it works in patients with diffuse large B-cell lymphoma (DLBCL). Patients will get one infusion after chemotherapy to prepare their body. The main goal is to check safety and see how many patients have a complete response by Week 13. About 160 patients will take part, and researchers will follow them for up to 15 years.",[55,56,57,26],"Lymphoma Diffuse Large B-cell","Leukemia and Lymphoma","Leukemia Relapse","2026-04-01",{"date":60,"type":31},"2026-04-02",{"date":62,"type":31},"2026-01-06",{"date":64,"type":20},"2029-11-02",{"name":66,"class":67},"AvenCell Therapeutics, Inc.","INDUSTRY",13,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":39},"100370740","looking-at-cognitive-and-brain-changes-in-people-with-lymphoma-receiving-car-t-therapy-100370740","NCT04107285","Looking at Cognitive and Brain Changes in People With Lymphoma Receiving CAR-T Therapy","A Study of Longitudinal Neurocognitive and Neuroimaging Evaluations for Adult Patients With Lymphoma Receiving CD19 CAR T Cell Therapy","Inclusion Criteria:\n\n* Patients must be 18 years of age or older\n* Planned treatment with commercial CD19-specific CAR T cells (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, or brexacabtagene autoleucel) for lymphoma.\n* Patients must have adequate end organ function for CAR T cell therapy\n\n  * Eastern Cooperative Group (ECOG) performance status of 0 to 2\n  * Meet cardiac, pulmonary, hematologic, hepatic, and renal requirements for CART therapy as described in corresponding product package insert\n* No evidence of central nervous system disease at study entry\n* Fluent and able to communicate well enough in English to complete the study assessments and provide informed consent, in the judgment of the consenting professional. o Patients who report that English is not their primary language will be asked the US Census English proficiency question: \"How well do you speak English,\" and the answer \"very well\" will be required\n\nExclusion Criteria:\n\n* Signs and\u002For symptoms of central nervous system cancer (e.g., metastases, leptomeningeal disease) as determined by their physician, medical records, or by a brain MRI, either at the time of enrollment or during the study period.\n* Current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient report\n* History of neurodegenerative disease, or traumatic brain injury with loss of consciousness (\\>60 minutes), as per medical records or patient report\n* A history of epilepsy as per medical records or patient report\n* Current ongoing substance abuse and\u002For history of substance abuse, as per medical records or patient report\n* Evidence of visual or auditory impairment that would preclude completion of the assessments, as per medical records or patient report\n* Contraindications to MRI examinations as per standard screening guidelines used in the Department of Radiology (i.e., ferromagnetic material or implants, pacemakers or defibrillators, stents, claustrophobia)",{"count":77,"type":20},120,"OBSERVATIONAL","The purpose of this study is to learn about possible changes in cognitive (mental) abilities, such as memory skills and concentration, and in brain anatomy (structure) and function, in people with lymphoma receiving CAR-T therapy.",[26],[82,83,84],"Neurocognitive Evaluations","Neuroimaging Evaluations","19-268","2025-10-23",{"date":87,"type":31},"2025-10-24",{"date":89,"type":31},"2019-09-25",{"date":91,"type":20},"2026-09",{"name":93,"class":38},"Memorial Sloan Kettering Cancer Center"]